Connection

Daniel Wrapp to Humans

This is a "connection" page, showing publications Daniel Wrapp has written about Humans.
Connection Strength

0.022
  1. Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell Rep Med. 2021 06 15; 2(6):100313.
    View in: PubMed
    Score: 0.002
  2. Prolonged evolution of the human B cell response to SARS-CoV-2 infection. Sci Immunol. 2021 02 23; 6(56).
    View in: PubMed
    Score: 0.002
  3. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science. 2021 02 19; 371(6531):823-829.
    View in: PubMed
    Score: 0.002
  4. Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape. Nat Commun. 2021 01 20; 12(1):469.
    View in: PubMed
    Score: 0.002
  5. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science. 2020 09 18; 369(6510):1501-1505.
    View in: PubMed
    Score: 0.002
  6. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science. 2020 08 07; 369(6504):731-736.
    View in: PubMed
    Score: 0.002
  7. Site-specific glycan analysis of the SARS-CoV-2 spike. Science. 2020 07 17; 369(6501):330-333.
    View in: PubMed
    Score: 0.002
  8. Iterative screen optimization maximizes the efficiency of macromolecular crystallization. Acta Crystallogr F Struct Biol Commun. 2019 Feb 01; 75(Pt 2):123-131.
    View in: PubMed
    Score: 0.002
  9. Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. Sci Rep. 2018 10 24; 8(1):15701.
    View in: PubMed
    Score: 0.002
  10. Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation. Immunity. 2018 02 20; 48(2):339-349.e5.
    View in: PubMed
    Score: 0.002
  11. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A. 2017 08 29; 114(35):E7348-E7357.
    View in: PubMed
    Score: 0.001
  12. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med. 2017 05 03; 9(388).
    View in: PubMed
    Score: 0.001
  13. Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state. Nat Commun. 2017 02 13; 8:14158.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.